For anyone in Socea trying to locate CJC-1295, the first thing to know is that this compound moves through online research channels. This matters because CJC-1295 quality varies dramatically across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor controls every quality variable. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram showing ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Socea researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Socea researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The first step for any Socea researcher sourcing CJC-1295 is finding vendors with verified community track records — search results alone are too heavily influenced by marketing spend. A COA for CJC-1295 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Community reputation in research forums is a complementary signal to COA verification — vendors with sustained positive community feedback have proved themselves through consistent results. For Socea researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Socea
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results expressed as EU/mg or EU/mL and confirm they fall within appropriate thresholds. The research literature on CJC-1295 should be reviewed carefully before beginning any research — study approaches, dose levels, and measured endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
